期刊文献+

融合蛋白TAP-SSL5对血小板微粒与THP-1细胞结合及Mac-1活化的影响 被引量:3

Fusion protein TAP-SSL5 suppresses binding of platelet microparticles to THP-1 cells and activation of Mac-1
在线阅读 下载PDF
导出
摘要 目的探讨融合蛋白TAP-SSL5对血小板微粒(platelet microparticles,PMPs)与人单核细胞株THP-1细胞结合及Mac-1活化的影响。方法以二磷酸腺苷(adenosine diphosphate,ADP)激活人血小板并获取PMPs。采用流式细胞仪(flow cytometry,FCM)及PE标记的抗CD62P单克隆抗体、FITC标记的Annexin V检测PMPs,以FITC标记的抗CD41单克隆抗体和PE标记的抗CD154(CD40L)单克隆抗体检测PMPs的表面特征。采用JC-1试剂盒检测血小板线粒体膜电位。采用FCM检测PMPs与THP-1细胞的结合,以及PMPs诱导THP-1细胞表面Mac-1(CD11b/CD18,αMβ2)的活化情况,并研究TAP-SSL5的干预作用。结果 PMPs呈现CD62P和Annexin V双阳性,且CD41和CD40L的阳性率分别达到50.8%和44.0%。JC-1检测显示,ADP对血小板线粒体膜电位无明显影响(P>0.05)。PMPs与THP-1细胞的结合率为(24.80±5.16)%,PMPs诱导THP-1细胞Mac-1的活化率为(21.17±5.92)%,THP-1细胞经10 mg/L TAP-SSL5预处理后,PMPs的结合率下降至(13.67±2.15)%(P<0.05),Mac-1的活化率下降至(0.99±0.62)%(P<0.01)。结论 TAPSSL5可抑制PMPs与THP-1细胞的结合及THP-1细胞表面Mac-1的活化。 Objective To investigate the effect of anticoagulant and anti-inflammatory fusion protein TAP-SSL5 (tick anticoagulant peptide and staphylococcal superantigen like protein-5) on the binding of platelet microparticles (PMPs) to human acute monocytic leukemia cell line THP-1 and the activation of Mac-1. Methods PMPs were generated by adenosine diphosphate (ADP) activating human platelets. Flow cytometry (FCM) was used to identify PMPs by PE labeled mouse anti-human CD62P monoclonal antibody and FITC-Annexin V, and to check the activation and phosphatidylserine (PS) by FITC labeled mouse anti-human CD41 monoclonal antibody and PE labeled mouse anti-human CD151 monoclonal antibody (CD40L). The mitochondrial membrane potential in human platelets was checked with JC-1 kit. The binding rates of PMPs to THP-1 cells and the conformation change of Mac-1 (CD11b/CD18, αMβ2) after co-incubation with PMPs were assayed by FCM. Results Both CD62P and PS were positive on PMPs. The positive rates of CD41 and CD40L on the ADP-induced PMPs were 50.8% and 44.0% respectively. While there was no significant change on the mitochondrial membrane potential in ADP activated platelets (P〉0.05). The binding rates of PMPs to THP-1 cells and the activation rates of Mac-1 on THP-1 cells were (24.80±5.16)% and (21.17±5.92)% respectively, which decreased to (13.67±2.15)% and (0.99±0.62)% after the THP-1 cells were pre-incubated with 10 mg/L TAP-SSL5 (P〈0.05 and P〈0.01). Conclusion TAP-SSL5 directly inhibits the binding of PMPs to THP-1 cells, and subsequently inhibits the activation of Mac-1 on THP-1 cells.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2014年第9期864-867,共4页 Journal of Third Military Medical University
基金 国家自然科学基金(81270362) 国家重大新药创制课题(2013ZX09103003-001)~~
关键词 血小板微粒 金黄色葡萄球菌超抗原样蛋白-5 蜱抗凝血肽 融合蛋白 THP-1细胞 MAC-1 platelet microparticles staphylococcal superantigen like protein-5 anti-coagulant tick anticoagulant peptide fusion protein THP-1 cells Mac-1
  • 相关文献

参考文献23

  • 1Liu M L, Williams K J. Microvesicles: potential markers and mediators of endothelial dysfunction [ J]. Curt Opin Endocrinol Diabetes Obes, 2012, 19(2): 121-127.
  • 2Libby P. Inflammation in atherosclerosis [ J ]. Arterioscler Thromb Vasc Biol, 2012, 32(9) : 2045 -2051.
  • 3Georgescu A, Alexandru N, Andrei E, et al. Circulating microparti- cles and endothelial progenitor cells in atherosclerosis : pharmacologicaleffects of irbesartan[ J]. J Thromb Haemost, 2012, 10 (4) : 680 - 691.
  • 4Angelillo-Scherrer A. Leukocyte-derived microparticles in vascular ho- meostasis[J]. Circ Res, 2012, 110(2) : 356-369.
  • 5Leroyer A S, Tedgui A, Boulanger C M. Role of microparticles in atherothrombosis[ J]. J Intern Med, 2008, 263(5) : 528 -537.
  • 6Semple J W, Italiano J E Jr, Freedman J. Platelets and the immune continuum[J]. Nat Rev Immunol, 2011, 11(4) : 264-274.
  • 7Nurden A T. Platelets, inflammation and tissue regeneration [ J ]. Thromb Haemost, 2011, 105(Suppl 1) : S13- S33.
  • 8Rosenfeld M E. Inflammation and atherosclemsis : direct versus indirect mechanisms[J]. Curt Opin Pharmaeol, 2013, 13(2): 154-160.
  • 9Burger D, Schock S, Thompson C S, et al. Microparticles: biomarkers and bevondr [J] Clin Sci (Lond). 2013. 124(7) : 423 -441.
  • 10Bestebroer J, Poppelier M J, Ulfman L H, et al. Staphylococcal su- perantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neu- trophil roiling [ J ]. Blood, 2007, 109 (7) : 2936 - 2943.

二级参考文献47

  • 1Schwarz M, Meade G, Stoll P, et al. Conformation-specific blockade of the integrin GPⅡb/Ⅲa: a novel antiplatelet strategy that selectively targets activated platelets[J]. Circ Res, 2006, 99( 1 ) : 25 - 33.
  • 2Strukova S. Blood coagulation-dependent inflammation. Coagulation- dependent inflammation and inflammation-dependent thrombosis [J]. Front Biosc, 2006, 11 : 59 - 80.
  • 3Constantin G. PSGL-1 as a novel therapeutic target [J]. Drug News Perspect, 2004, 17(9) : 579 -586.
  • 4Bestebroer J, Poppelier M J, Ulfman L H, et al. Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling[J]. Blood, 2007, 109(7) : 2936 -2943.
  • 5Jordan S P, Waxman L, Smith D E, et al. Tick anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa[J]. Biochemistry, 1990, 29(50) : 11095 - 11100.
  • 6Hansson G K, Libby P. The immune response in atherosclerosis: a double-edged sword [J]. Nat Rev Immunol, 2006, 6 (7) : 508 - 519.
  • 7Bestebroer J, van-Kessel K P, Azouagh H, et al. Staphylococcal SSL5 inhibits leukocyte activation by chemokines and anaphylatoxins [J]. Blood, 2009, 113(2) : 328 -337.
  • 8Baker H M, Basu I, Chung M C, et al. Crystal structures of the staph- ylococcal toxin SSL5 in complex with sialyl Lewis X reveal a conserved binding site that shares common features with viral and bacterial sialic acid binding proteins[J]. J Mol Biol, 2007, 374 (5) : 1298 - 1308.
  • 9Hagemeyer C E, Tomic I, Jaminet P, et al. Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide[J]. Thromb Haemost, 2004, 92( 1 ) : 47 - 53.
  • 10Stoll P, Bassler N, Hagemeyer C E, et al. Targeting ligand-induced binding sites on GPⅡb/Ⅲa via single-chain antibody allows effective anticoagulation without bleeding time prolongation [J]. Arterioscler Thromb Vasc Biol, 2007, 27(5) : 1206 -1212.

共引文献11

同被引文献21

  • 1Jy W, Horstman L L, Jimenez J J, et al. Measuring circulating cell-derived microparticles[J]. J Thromb Haemost, 2004, 2(10): 1842-1851.
  • 2Piccin A, Murphy W G, Smith O P. Circulating microparticles: pathophysiology and clinical implications[J]. Blood Rev, 2007, 21(3): 157-171.
  • 3Carcao M D, van-den-Berg H M, Ljung R, et al. Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A[J]. Blood, 2013, 121(19): 3946-3952, S1.
  • 4Dovlatova N, Lordkipanidze M, Lowe G C,et al. Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders[J]. J Thromb Haemost, 2014, 12(5): 660-665.
  • 5Watson S P, Lowe G C, Lordkipanidze M,et al. Genotyping and phenotyping of platelet function disorders[J]. J Thromb Haemost, 2013, 11(Suppl 1): 351-363.
  • 6Grunewald M, Siegemund A, Grunewald A,et al. Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia[J]. Haemophilia, 2002, 8(6): 768-775.
  • 7Santagostino E, Mancuso M E, Tripodi A,et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile[J]. J Thromb Haemost, 2010, 8(4): 737-743.
  • 8van-Bladel E R, Roest M, de-Groot P G,et al. Up-regulation of platelet activation in hemophilia A[J]. Haematologica, 2011, 96(6): 888-895.
  • 9van-Dijk K, van-der-Bom J G, Fischer K,et al. Phenotype of severe hemophilia A and plasma levels of risk factors for thrombosis[J]. J Thromb Haemost, 2007, 5(5): 1062-1064.
  • 10Celi A, Lorenzet R, Furie B C,et al. Microparticles and a P-selectin-mediated pathway of blood coagulation[J]. Dis Markers, 2004, 20(6): 347-352.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部